MAXHEALTH

Max Healthcare Institute share price & financials

Price
₹1,089.9
Market cap
₹97.2k Cr
Sector
Healthcare
Calls analysed
7
Latest concall · Q1 FY27 · call held 14 Aug 2026

Max Healthcare Institute Limited Q1 FY27

Revenue ₹2,982 cr +16%Operating EBITDA ₹704 cr +15%Operating EBITDA Margin 24.8% PAT ₹357 cr +3%

What went well

  • Revenue of ₹2,982 crore, up 16% YoY and 12% QoQ.
  • Operating EBITDA of ₹704 crore, up 15% YoY and 3% QoQ.
  • Average occupancy for the Network continued to be more than 75% despite a 13% increase in operational bed capacity year-on-year.

What to watch

  • Operating EBITDA margin was 24.8%, compared to 24.9% in Q1 FY26 and 26.8% in trailing quarter, muted due to new capacities and Kalinga acquisition.
  • Share of oncology for in-patient revenues dropped to 22% from 26% in Q1 FY26 due to discontinuation of select high-value chemotherapy drugs.
Read the full call →

What Max Healthcare Institute Limited does

Max Healthcare Institute Limited operates a network of quaternary/tertiary-care hospitals and standalone speciality clinics concentrated in Delhi NCR, with additional facilities in Gurugram, Noida, Mumbai, Lucknow, Mohali, Dehradun, Bathinda, Nagpur and Bhubaneshwar. It earns primarily by delivering inpatient hospital care — complex surgeries, transplants and cancer treatment — plus diagnostics and outpatient consultations, across a mix of owned hospitals, asset-light leased/built-to-suit facilities and operations-and-management (O&M) contracts. Beyond hospitals, it runs Max Lab (non-captive pathology/diagnostics) and Max@Home (homecare services) as capital-light adjacent businesses, and operates a network of international Patient Assistance Centres to serve medical-value-travel patients. The group also partners with global academic institutions on medical research, publications and clinical training programs.

Segments

  • Hospitals
  • Max Lab
  • Max@Home
Current bed capacity
6,000+ beds
Hospital network size
21 facilities (hospitals and standalone speciality clinics)
Market position
India's second-largest hospital chain by revenue and EBITDA among listed peers (FY26)
Geographic footprint
Facilities across Delhi NCR plus Gurugram, Noida, Mumbai, Lucknow, Mohali, Dehradun, Bathinda, Nagpur and Bhubaneshwar
Beds in metro cities
4,400+ beds (~73% of total capacity)
International patient network
15 company- and partner-owned Patient Assistance Centres across 14 countries
Founded 2001Headquarters Gurugram, Haryana, India Company website

Guidance record · Q1 FY27

what the last two calls moved 25 tracked 3 delivered 1 missed 21 open
  • CGHS rate revision delivered said Q3 FY25 Promised: expecting better rates coming through on CGHS now... hope is that this comes in this quarter. Q1 FY27: No new update. Promise was achieved in Q2 FY26.
  • Institutional price increase went quiet said Q3 FY25 Promised: should come within a month or two Q1 FY27: No update provided on the specific institutional price increase. Promise remains ghosted since Q4 FY25.
  • Max Smart (Saket Complex) 400 beds completion delayed said Q3 FY25 Promised: completion within Q1 FY '26 Q1 FY27: Operationalized 50% of the 400-bed tower. The remaining 50% are expected to be handed over in the current quarter (Q2 FY27).

All 25 tracked — every revision, and every one management stopped mentioning.

Open the guidance ledger

Quarterly results

Q1 FY27: revenue up 16.7%, net profit up 4.9% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue1,707 1,868 1,910 2,028 2,135 +25%2,068 +11%2,143 +12%2,366 +17%
EBITDA451 499 512 523 575 +27%538 +8%606 +18%598 +14%
Net profit282 239 319 308 491 +74%301 +26%342 +7%323 +5%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −12.1% 1Y

₹1.0k₹1.1k₹1.2kSept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Q2 FY26 — 21 Nov 2025Q3 FY26 — 6 Feb 2026Q4 FY26 — 22 May 2026Q1 FY27 — 14 Aug 2026

1Y: ₹1,180.7 on 10 Sept 2025 → ₹1,037.7. High ₹1,211 (23 Oct 2025), low ₹931.6 (6 Apr 2026).

How the price took the results

close before → close after

Q1 FY27
−0.5%
14 Aug
Q4 FY26
−6.2%
22 May
Q3 FY26
−0.1%
6 Feb
Q2 FY26
+1.0%
21 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Financials, as filed

Revenue grew 29.0% a year over 3 years, FY23 to FY26. Operating margin narrowed to 26.8%.

Year endingFY23FY24FY25FY26
Revenue₹3.9k Cr₹5.4k Cr₹7.0k Cr₹8.4k Cr
Operating profit₹1.1k Cr₹1.5k Cr₹1.8k Cr₹2.2k Cr
Operating margin27.6%27.6%26.3%26.8%
Interest₹77 Cr₹60 Cr₹165 Cr₹236 Cr
Depreciation₹203 Cr₹245 Cr₹360 Cr₹446 Cr
Net profit₹1.0k Cr₹1.1k Cr₹1.1k Cr₹1.4k Cr
Net margin25.7%19.6%15.3%17.2%
Cash from operations₹1.2k Cr₹1.1k Cr₹1.4k Cr₹1.6k Cr
Free cash flow₹877 Cr₹342 Cr₹500 Cr₹165 Cr
ROCE15.0%16.0%15.0%15.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹966 Cr₹970 Cr₹971 Cr₹972 Cr₹972 Cr₹973 Cr
Reserves₹4.7k Cr₹5.3k Cr₹6.4k Cr₹7.4k Cr₹7.5k Cr₹9.8k Cr
Borrowings₹1.1k Cr₹913 Cr₹689 Cr₹1.3k Cr₹705 Cr₹3.5k Cr
Other liabilities₹1.8k Cr₹2.0k Cr₹2.0k Cr₹2.3k Cr₹1.2k Cr₹3.0k Cr
Total liabilities₹8.5k Cr₹9.2k Cr₹10.1k Cr₹12.0k Cr₹10.4k Cr₹17.2k Cr
Fixed assets₹6.5k Cr₹7.0k Cr₹7.0k Cr₹8.8k Cr₹4.9k Cr₹13.0k Cr
Capital work in progress₹27 Cr₹151 Cr₹252 Cr₹553 Cr₹345 Cr₹593 Cr
Investments₹1 Cr₹1 Cr₹1 Cr₹2 Cr₹2.6k Cr₹5 Cr
Other assets₹2.0k Cr₹2.0k Cr₹2.8k Cr₹2.7k Cr₹2.5k Cr₹3.6k Cr
Total assets₹8.5k Cr₹9.2k Cr₹10.1k Cr₹12.0k Cr₹10.4k Cr₹17.2k Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, FIIs trimmed −12.98 pp while DIIs added +12.54 pp. The shareholder count grew 39% to 2,24,606.

Promoters
23.7%
FIIs
41.8%
DIIs
29.9%
Public
4.5%

Since Jun 2025

  • FIIs −12.98 pp
  • DIIs +12.54 pp
  • Public +0.46 pp

How it drifted, 12 quarters

Over this window FIIs fell from 60.4% to 41.8% — −18.6 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 23.8%, FIIs 60.4%, DIIs 11.4%, Public 4.5%.Dec '23: Promoters 23.8%, FIIs 60.7%, DIIs 11.6%, Public 4.0%.Mar '24: Promoters 23.8%, FIIs 57.3%, DIIs 15.0%, Public 4.0%.Jun '24: Promoters 23.7%, FIIs 57.0%, DIIs 15.4%, Public 3.9%.Sep '24: Promoters 23.7%, FIIs 57.3%, DIIs 15.1%, Public 3.8%.Dec '24: Promoters 23.7%, FIIs 56.9%, DIIs 15.6%, Public 3.8%.Mar '25: Promoters 23.7%, FIIs 54.7%, DIIs 17.6%, Public 3.9%.Jun '25: Promoters 23.7%, FIIs 54.8%, DIIs 17.4%, Public 4.1%.Sep '25: Promoters 23.7%, FIIs 51.8%, DIIs 20.0%, Public 4.4%.Dec '25: Promoters 23.7%, FIIs 50.5%, DIIs 21.2%, Public 4.5%.Mar '26: Promoters 23.7%, FIIs 45.4%, DIIs 26.3%, Public 4.6%.Jun '26: Promoters 23.7%, FIIs 41.8%, DIIs 29.9%, Public 4.5%.

Who was buying across the market this quarter →

Who bought this quarter

since Mar 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 3 holders trimming and 5 off the list — both are in the register beside this.

Who is on the register

Named in the Jun 2026 filing

Every holder of Max Healthcare Institute Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Abhay Soi 23.71%unchanged
NPS Trust A/C through various schemes Pension / PF3.45%newly disclosed
New World Fund Inc Global fund house3.29%−0.41 pp
Government Of Singapore - E Sovereign3.28%−0.10 pp
HDFC Mutual Fund through various schemes Mutual fund3.04%+0.41 pp
Life Insurance Corporation of India through various schemes Insurer3.00%newly disclosed
SBI Mutual Fund through various schemes Mutual fund2.55%unchanged
Invesco Mutual Fund through various schemes Mutual fund2.19%+0.22 pp
ICICI Prudential Mutual Fund through various schemes Mutual fund1.69%+0.47 pp
Nippon India Mutual Fund through various schemes Mutual fund1.53%+0.12 pp
Axis Max Life Insurance Limited through various schemes Insurer1.46%newly disclosed
Canara Robeco Mutual Fund through various schemes Mutual fund1.43%+0.06 pp

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Mutual funds in MAXHEALTH

Filings to Aug 2026

1 new, 14 added, 8 trimmed, 1 sold out — net +10.11 L shares (+1.5%).

Held by funds
₹7.2k Cr
32 schemes
Biggest holder
HDFC Flexi Cap Fund
₹1.6k Cr · 1.5% of that fund
SchemeHoldingLast month
HDFC Flexi Cap Fund HDFC Mutual Fund₹1.6k Crheld
SBI Nifty 50 ETF SBI Mutual Fund₹1.5k Cr+0.76 L
Nippon India Growth Mid Cap Fund Nippon India Mutual Fund₹761 Cr+5.00 L
SBI Aggressive Hybrid Fund SBI Mutual Fund₹729 Crheld
HDFC Large Cap Fund HDFC Mutual Fund₹726 Crheld
Nippon India ETF Nifty 50 BeES Nippon India Mutual Fund₹472 Cr+0.91 L
Nippon India Pharma Fund Nippon India Mutual Fund₹277 Crheld
SBI Healthcare Opportunities Fund SBI Mutual Fund₹250 Cr+1.50 L

HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.

Mutual funds Aug 2026

14 added, 8 trimmed — net +10.11 L shares (+1.5%)

Funds are sitting on
+13%
vs est. average cost
Held by funds
₹7.2k Cr
32 schemes · ≈ 7.6% of the company
Biggest holder
HDFC Flexi Cap Fund
₹1.6k Cr · 1.5% of that fund
Longest holder
SBI Healthcare Opportunities Fund
5y 1m · since Aug '21

Shares held by these funds +25%

Aug '23 6.70 cr shares Jul '26

What the price assumes

Growth trap

To justify its price of ₹1038, this stock must grow earnings at 38% every year for 7 years. Our analysis caps realistic growth at ~13%. At that growth it is worth ₹299 — downside of 71%.

Growth the price implies
37.6% a year
for 7 years, fading to 4%
It has actually compounded at
12.9% a year
net profit, FY23–FY26 · EPS 12.8%
The gap
0.2 pp
-71% downside if it only repeats history
Price today ₹1,037.7 Value at the reference growth ₹299.29

Change the assumptions yourself →

All earnings calls (7)

Read the Q1 FY27 call →